Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will release interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis on December 18, 2024. The trial is a randomized, double-blind, placebo-controlled study evaluating the drug in patients with moderate to severe atopic dermatitis. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to present the data, which will also be released via press release. The presentation will include slides and be accessible through a toll-free domestic line or international dial-in, with a webcast replay available on the company's website for 60 days.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato che rilascerà dati intermedi dal suo trial clinico di Fase 1 su soquelitinib per la dermatite atopica il 18 dicembre 2024. Lo studio è un trial randomizzato, in doppio cieco e controllato con placebo che valuta il farmaco in pazienti con dermatite atopica da moderata a grave. L'azienda organizzerà una conferenza telefonica e una diretta web alle 8:00 a.m. ET / 5:00 a.m. PT per presentare i dati, che saranno resi noti anche tramite comunicato stampa. La presentazione includerà diapositive ed sarà accessibile tramite una linea nazionale senza costi o chiamata internazionale, con una registrazione della diretta disponibile sul sito web dell'azienda per 60 giorni.
Corvus Pharmaceuticals (NASDAQ: CRVS) anunció que publicará datos interinos de su ensayo clínico de Fase 1 sobre soquelitinib para dermatitis atópica el 18 de diciembre de 2024. El ensayo es un estudio aleatorizado, doble ciego y controlado con placebo que evalúa el medicamento en pacientes con dermatitis atópica de moderada a severa. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo a las 8:00 a.m. ET / 5:00 a.m. PT para presentar los datos, que también se publicarán a través de un comunicado de prensa. La presentación incluirá diapositivas y será accesible a través de una línea nacional gratuita o llamada internacional, con una repetición de la transmisión disponible en el sitio web de la compañía durante 60 días.
코르부스 제약(Corvus Pharmaceuticals) (NASDAQ: CRVS)는 소콜리티닙(soquelitinib)의 아토피 피부염에 대한 1상 임상 시험의 중간 데이터를 2024년 12월 18일에 발표할 것이라고 발표했습니다. 이 시험은 중등도에서 중증의 아토피 피부염 환자에게 약물을 평가하는 무작위 이중 맹검 위약 대조 연구입니다. 회사는 데이터를 제시하기 위해 동부 표준시 기준 오전 8시 / 태평양 표준시 기준 오전 5시에 컨퍼런스 콜 및 웹캐스트를 진행하며, 데이터는 보도 자료를 통해서도 발표될 예정입니다. 발표에는 슬라이드가 포함되며, 무료 국내 전화 또는 국제 전화 접속이 가능하며, 회사 웹사이트에서는 60일 동안 웹캐스트 재생이 가능합니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a annoncé qu'elle publiera les données intermédiaires de son essai clinique de Phase 1 sur soquelitinib pour la dermatite atopique le 18 décembre 2024. L'essai est une étude randomisée, en double aveugle et contrôlée par placebo évaluant le médicament chez des patients atteints de dermatite atopique modérée à sévère. La société organisera une conférence téléphonique et un webinaire à 8h00 HE / 5h00 HP pour présenter les données, qui seront également publiées par un communiqué de presse. La présentation inclura des diapositives et sera accessible par un numéro national gratuit ou une ligne internationale, avec une rediffusion du webinaire disponible sur le site Web de la société pendant 60 jours.
Corvus Pharmaceuticals (NASDAQ: CRVS) gab bekannt, dass am 18. Dezember 2024 vorläufige Daten aus seiner Phase-1-Studie zu soquelitinib bei atopischer Dermatitis veröffentlicht werden. Die Studie ist eine randomisierte, doppelblinde, placebokontrollierte Untersuchung, die das Medikament bei Patienten mit mittelschwerer bis schwerer atopischer Dermatitis evaluiert. Das Unternehmen wird um 8:00 Uhr ET / 5:00 Uhr PT eine Telefonkonferenz und einen Webcast abhalten, um die Daten zu präsentieren, die auch über eine Pressemitteilung veröffentlicht werden. Die Präsentation wird Folien beinhalten und über eine gebührenfreie nationale Linie oder internationale Einwahl zugänglich sein, mit einer Wiederholung des Webcasts, die 60 Tage lang auf der Website des Unternehmens verfügbar sein wird.
- None.
- None.
Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call and webcast.
Conference Call, Webcast and Presentation Slides
Corvus will host a conference call and webcast tomorrow, Wednesday, December 18, 2024 at 8:00 a.m. ET / 5:00 a.m. PT to provide an overview of the soquelitinib atopic dermatitis Phase 1 clinical data. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 60 days.
About Soquelitinib
Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation which has the potential to suppress autoimmune and inflammatory reactions. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company has initiated a registrational Phase 3 clinical trial (NCT06561048) of soquelitinib in patients with relapsed peripheral T cell lymphoma. Soquelitinib is also now being investigated in a randomized placebo-controlled phase 1 clinical trial in patients with atopic dermatitis. A recent publication describing the chemistry, enzymology and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the Nature website and on the Publications and Presentations page of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals (CRVS) release interim data for its soquelitinib atopic dermatitis trial?
What type of clinical trial is CRVS conducting for soquelitinib in atopic dermatitis?
How can investors access CRVS's soquelitinib data presentation on December 18?
How long will the replay of CRVS's soquelitinib data presentation be available?
